Research Study

A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Assess the Efficacy and Safety of Clazosentan in Preventing Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI), in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH)
Principal Investigator 
Gary Redekop

Overview

Body Locations and Systems 
Aneurysm
ClinicalTrials.gov# 
NCT03585270
Status 
Recruiting
Study Start/End 
Jun 4, 2019 to Dec 31, 2020
Locations 
Vancouver General Hospital
Name/Title 
Angela Brevner, Research Coordinator
Phone 
604-875-4130
Purpose of Study 

The purpose of this study is to evaluate if clazosentan (on top of normal routine medical care) can reduce the risk of developing complications related to cerebral vasospasm and permanent brain damage as compared to normal routine medical care alone.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.